Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes
CONCLUSION: Adding ezetimibe to a moderate-intensity statin in patients with type 2 diabetes has a greater LDL-C-lowering effect and greater primary prevention of composite outcomes than that of high-intensity statin monotherapy.PMID:38175670 | DOI:10.1210/clinem/dgad714
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: So Young Park Ji Eun Jun In-Kyung Jeong Kyu Jeung Ahn Ho Yeon Chung You-Cheol Hwang Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Databases & Libraries | Diabetes | Diabetes Type 2 | Endocrinology | Health Insurance | Heart | Heart Attack | Insurance | Statin Therapy | Stroke | Study | Vytorin | Zetia